Quantcast

Latest spironolactone Stories

2014-05-19 12:46:46

European Society of Cardiology TOPCAT fails to meet primary endpoint but post-hoc analysis shows benefit in patients from Americas Clinicians have been urged to consider using spironolactone in their patients with heart failure and preserved ejection fraction (HFPEF) after a post-hoc analysis of the TOPCAT trial showed benefit in patients from the Americas. The research was presented today at the Heart Failure Congress 2014 in Athens, Greece. The Congress is the main annual meeting...

2014-04-10 09:55:23

Findings from the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial, have revealed that adding the medication known as spironolactone (Aldactone) to existing therapy did not significantly reduce the composite time to either death from cardiovascular causes, surviving a cardiac arrest, or hospitaliization to manage heart failure in patients with heart failure and a preserved ejection fraction in a study funded by the National Heart, Lung and...

2013-02-27 10:59:47

Among patients with heart failure with preserved ejection fraction, long-term treatment with the medication spironolactone improved left ventricular diastolic function but did not affect maximal exercise capacity, patient symptoms, or quality of life, according to a study appearing in the February 27 issue of JAMA. "Heart failure (HF) with preserved ejection fraction [EF; the percentage of blood that is pumped out of a filled ventricle as a result of a heartbeat is 50 percent or greater]...

2012-11-28 13:08:16

A large study addressing the effectiveness and safety of aldosterone antagonist therapy for older heart failure patients has found notable differences between the drug's results in clinical trial vs. what occurs in actual practice, according to researchers at Duke Medicine. Those differences have been noted anecdotally by doctors, and likely contributed to the slow adoption of aldosterone antagonists in clinical practice, but they had not been confirmed in a large study examining the drugs...

2011-09-19 21:59:01

Clinical trial investigator Bertram Pitt, M.D., to provide overview of research at conference sponsored by the American Physiological Society Roughly 5 million people in the United States live with heart failure, a condition in which the heart is unable to pump blood around the body effectively. The causes and types of heart failure vary greatly, and treatment must be tailored to each patient. In some cases, doctors will prescribe a class of diuretic drugs called aldosterone antagonists....

2011-05-23 13:21:09

Strong case for the use of eplerenone in patients with mild heart failure The aldosterone antagonist eplerenone (Inspra, Pfizer) significantly reduced the development of new onset atrial fibrillation and flutter (AFF) in patients with class 2 heart failure, concludes a sub-analysis of the EMPHASIS-HF trial, presented at the Heart Failure Congress 2011, organized by the Heart Failure Association of the European Society of Cardiology (ESC). The analysis, presented in Late Breaking Session 1,...

2010-11-14 08:00:00

CHICAGO, Nov. 14, 2010 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) today announced results from the EMPHASIS-HF trial(1) showing a statistically significant reduction in risk of cardiovascular (CV) death or heart failure (HF) hospitalization for patients with chronic heart failure with mild symptoms treated with Inspra® (eplerenone) versus those given placebo in addition to standard HF therapy. The results were presented to physicians attending the American Heart...

2009-10-21 09:32:53

A study published in JAMA on October 21 by Nancy M. Albert and colleagues, exploring aldosterone antagonist usage among US patients hospitalized with heart failure, found that only one-third of patients meeting current US Clinical Practice Guidelines criteria were actually being treated (1). Furthermore, the observational analysis of 43,625 patients admitted with heart failure and discharged home from 241 hospitals participating in the "ËœGet With IT Guidelines', showed that...

2009-06-01 10:52:43

Even while their blood pressures are still normal, overweight male teens may have elevated levels of a hormone known to increase pressures as well as early signs of heart damage, researchers say. Medical College of Georgia researchers looking at 126 healthy 15- to17-year-olds in high school in Augusta, Ga., found the hormone aldosterone highest among the overweight males. Early intervention could help these young people avoid growing up to be adults with cardiovascular disease, the number...


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related